Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Blood creatine phosphokinase, Laboratory test, Muscular weakness, Pain
Clinical narrative: Rhabdomyolysis; severe pain and weakness in my upper legs and upper arms, shoulders, about 3 days after vaccine injection; severe pain and weakness in my upper legs and upper arms, shoulders, about 3 days after vaccine injection; severe pain and weakness in my upper legs and upper arms, shoulders, about 3 days after vaccine injection; Injection site pain; body aches; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 13May2022 as dose 4 (booster), single (Lot number: F84989) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "known allergies: Penicillins" (unspecified if ongoing); "High blood pressure" (unspecified if ongoing); "depression" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing); "obesity" (unspecified if ongoing); "scoliosis" (unspecified if ongoing); "osteoarthritis" (unspecified if ongoing); "fibromyalgia" (unspecified if ongoing); "known allergies: Meloxicam, Clindamycin" (unspecified if ongoing). Concomitant medication(s) included: SERTRALINE; AMLODIPINE; ROSUVASTATIN; IPRATROPIUM. Vaccination history included: BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Batch/Lot No: FF8839, Location of injection: Arm Left), administration date: 27Sep2021, when the patient was 67-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 2, SINGLE, Batch/Lot No: EN6207, Location of injection: Arm Left), administration date: 13Mar2021, when the patient was 66-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 1, SINGLE, Batch/Lot No: EL6207, Location of injection: Arm Left), administration date: 20Feb2021, when the patient was 66-year-old, for COVID-19 Immunization; Shingrix (Dose: 01, no testing documentation but experienced similar reaction after first dose of Shingrix vaccine in Mar2022), administration date: Mar2022, when the patient was 67 years old. The following information was reported: VACCINATION SITE PAIN (medically significant) with onset 13May2022, outcome "recovered", described as "Injection site pain"; PAIN (medically significant) with onset 13May2022, outcome "recovered", described as "body aches"; ARTHRALGIA (medically significant), PAIN IN EXTREMITY (medically significant), MUSCULAR WEAKNESS (medically significant) all with onset 16May2022, outcome "recovered" and all described as "severe pain and weakness in my upper legs and upper arms, shoulders, about 3 days after vaccine injection"; RHABDOMYOLYSIS (medically significant), outcome "unknown". The events "severe pain and weakness in my upper legs and upper arms, shoulders, about 3 days after vaccine injection", "injection site pain" and "body aches" required physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: Blood creatine phosphokinase: Over 20000, notes: Doctor ran tests, including CK, which was over 20,000 and was diagnosed with Rhabdomyolysis; tests: Unknown result, notes: Doctor ran tests. Therapeutic measures were taken as a result of arthralgia, pain in extremity, muscular weakness, vaccination site pain, pain. The patient received IV saline in ER (emergency room). The patient had no COVID prior vaccination. No COVID testing was done post vaccination.